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Abstract.  Cancer-associated retinopathy (CAR), a 
paraneoplastic syndrome, is characterized by the de- 
generation of retinal photoreceptors under conditions 
where the tumor and its metastases have not invaded 
the eye. The retinopathy often is apparent before the 
diagnosis of cancer and may be associated with auto- 
antibodies that react with specific sites in the retina. 
We have examined the sera from patients with CAR to 
further characterize the retinal antigen. Western blot 
analysis of human retinal proteins reveals a prominent 
band at 26 kD that is labeled by the CAR antisera. 
Antibodies to the 26-kD protein were affinity-purified 
from complex CAR antisera and used for EM- 
immunocytochemical localization of the protein to 
the nuclei, inner and outer segments of both rod and 
cone cells.  Other antibodies obtained from the CAR 
sera did not label photoreceptors.  Using the affinity- 
purified antibodies for detection, the 26-kD protein, 
designated p26, was purified to homogeneity from the 
outer segments of bovine rod photoreceptor cells by 
Phenyl-Sepharose and ion exchange chromatography. 
Partial amino acid sequence of p26 was determined by 
gas phase Edman degradation and revealed extensive 
homology with a  cone-specific protein, visinin. Based 
upon structural relatedness, both the p26 rod protein 
and visinin are members of the calmodulin family and 
contain calcium binding domains of the E-F hand 
structure. 
variety of neurodegenerative diseases are known to 
be associated with different types of cancer,  even 
though the tumor and its metastases have not invaded 
the nervous system (Brain and Norris, 1965; Brain and Wil- 
kinson, 1965; Brain et al., 1951; Croft and Wilkinson, 1963; 
Denny-Brown,  1948;  Hawley et  al.,  1980;  Henson  and 
Urich, 1982; Minna and Bunn, 1982; Norris,  1972).  These 
"remote effects" of cancer, or paraneoplastic syndromes, are 
of undetermined etiology, although some studies have impli- 
cated viral, hormonal or toxic origins (Brain and Norris, 
1965;  Hawley et al.,  1980;  Sawyer et al.,  1976;  Schold et 
al.,  1979).  Alternatively, these degenerative diseases may 
stem from an autoimmune response that is directed towards 
antigens or epitopes found in both the tumor and specific 
neurons (Anderson et al., 1988; Keltner et al., 1983; Korn- 
guth et al., 1982).  Evidence supporting this connection has 
been presented in the case of Eaton-Lambert myasthenic 
syndrome, a  disease of the peripheral nervous system, in 
which the binding of autoantibodies at the neuromuscular 
junction interferes with the calcium-induced release of neu- 
rotransmitter (DeAizpurua et al.,  1988;  Kim and Neher, 
1988;  Newsom-Davis,  1985).  An autoimmune component 
also has been suggested in several diseases of  the central ner- 
vous system, including paraneoplastic cerebellar degenera- 
tion (Anderson et al., 1988; Furneaux et al., 1990; Greenlee 
and Lipton, 1986) and cancer-associated retinopathy (CAR) t 
(Buchanan et al.,  1984;  Grunwald et al.,  1985;  Keltner et 
al., 1983; Kornguth et al., 1982; Thirkill et al., 1987, 1989). 
Like other retinal degenerations, CAR spares the inner ret- 
ina while causing photoreceptors to degenerate (Buchanan 
et al.,  1984;  Keltner et al.,  1983).  However,  during CAR 
there is no evidence of  pigment migration or epiretinal mem- 
brane formation, as occurs in retinitis pigmentosa, nor are 
the vasculature or optic nerve head damaged (Buchanan et 
al., 1984). The inflammatory response characteristic of uve- 
itis is not associated with CAR. In spite of these differences, 
autoantibodies may be involved in all of these degenerative 
diseases of  the retina (see Tso, 1989 for review). Retinal anti- 
gens of 58-62,  145, and 205 kD have been observed to bind 
antisera obtained from patients with retinitis pigmentosa and 
age-related macular degeneration (Galbraith et al.,  1986; 
Gurne et al., 1989). An earlier study of CAR also identified 
a retinal antigen of 65 kD, as well as a low molecular weight 
protein of'o 20 kD (Grunwald et al., 1985). More recent and 
extensive studies of CAR have focused on a prominent retinal 
antigen of ,o23  kD  (Keltner et al.,  1983;  Thirkill et al., 
1987,  1989).  Several of these antisera cross-react with the 
1. Abbreviations used in this paper: BTP, bis [2-hydroxymethyl] (minotris- 
[hydroxymethyl]-methane; CAR, cancer-associated retinopathy; ROS,  rod 
outer segment. 
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speculation that autoantibodies  associated  with retinal  de- 
generations may be directed towards  cytoskeletal elements 
found in the tumor and retinal cells (Grunwald et al., 1985; 
Gurne et al.,  1989). 
The results  obtained from immunohistochemical studies 
using CAR antisera have been inconsistent; different popula- 
tions of retinal cells have been labeled by different CAR an- 
tisera (Kelmer et al.,  1983; Kornguth et al.,  1982;  Thirkill 
et al.,  1989).  Antibodies from these complex human  sera, 
however,  have not been afffinity-purified, therefore,  it is dif- 
ficult to associate a specific antibody with a particular label- 
ing pattern. Nor have EM-immunocytochemical studies been 
performed. For these reasons, the identity of the retinal anti- 
gen that binds the CAR autoantibodies and its precise local- 
ization remain uncertain. The functional identification of the 
CAR antigen  also has not been ascertained. 
In this paper we describe the affinity purification of anti- 
bodies from CAR antisera, and the use of these antibodies 
in parallel Western blot analyses and EM-immunocytochem- 
ical studies.  Using the sera from five individuals, we have 
identified a 26-kD CAR antigen that is localized with highest 
density to the cell bodies of the retinal  rods and cones but 
also is found in the inner and outer segments of both types 
of photoreceptors. Further, we have purified the CAR anti- 
gen to homogeneity using a convenient, two-step chromato- 
graphic procedure. Protein fragments  of the purified protein 
were subjected to amino acid sequence analysis, and the pro- 
tein was identified as a member of a family of calcium bind- 
ing proteins. With this identification in hand,  it may now be 
possible to examine tumors from patients afflicted with CAR 
and determine whether a calcium binding protein or shared 
determinant  is the antigenic source in their cancer cells. A 
further  comparison is warranted  for patients  with similar 
cancers but who do not exhibit the retinopathy. 
Materials and Methods 
Fluorescence Light Microscopy 
Two initial observations were made regarding the binding of CAR antisera 
1o sections of human retina. First, if eyecups or isolated retinas were fixed 
before rinsing with a Ringer's solution or other buffer,  the affinity-purified 
anti-human IgG used as a secondary antibody labeled the subretinal space 
from the tips of the outer segments to the outer limiting membrane. The 
detection of IgG may result from a minor permeability of the blood-retinal 
barrier in vivo, or more than likely, a breakdown of the barriers upon death. 
In either case, isolated and rinsed retinas were used in the majority of these 
experiments to avoid background labeling. Secondly, the binding of CAR 
antisora to sections of human retina was suppressed if the tissue bad been 
fixed with glutaraldehyde, therefore retinas were fixed for 3-12 h in 4% 
formaldehyde at room temperature. Retinas subsequently were embedded 
in acrylamide and frozen in cold isopentane before cryosectioning, as de- 
scribed by Johnson and Blanks (1984).  The buffer used for fixation and 
embedding was 0.1 M sodium cacodylate, pH 7.2. Other reagents used for 
labeling cryoseetions were prepared with a  Ringer's solution (130  mM 
NaC1, 2 mM KCI, 2 mM CaCI2, 2 mM MgSO4,  2 mM NaHCO3,  10 mM 
glucose, 50 mM sucrose, 10 mM Hepes, pH 7.5), and incubations were con- 
ducted at room temperature. 
In parallel experiments, fixed retinas were embedded in a hydrophilic 
plastic, LR White or LR Gold, as described below, and thick sections were 
processed for fluorescence microscopy. 
Sections were blocked for 30 rain at room temperature using a Ringer's 
solution containing 1% wt/vol BSA and 1% vol/vol normal goat serum. Sec- 
tions were washed and incubated with human CAR antisora or normal hu- 
man sera at a  dilution of 1:50 or 1:100 for 1 h. In some experiments, both 
cryosections and plastic sections were incubated overnight in a humidified 
chamber with antibodies which had been affinity-purified from CAR an- 
tisera (see below). After several washes, sections were incubated for 1 h 
with a biotinyl-goat anti-human IgG at a concentration of 25 #g/ml. Sec- 
tions finally were incubated for 1 h with a solution containing 50/~g/rnl of 
a  streptavidin-Texas red conjugate.  After dehydrating with ethanol and 
clearing with xylene, sections were viewed with a Zeiss Universal fluores- 
cence light microscope using X25 and X40 neofluor objectives. 
Electron Microscopy 
Isolated human  retinas  were  rinsed  with  Ringer's solution,  and  3-ram 
Trephine punches were fixed for 2 h or overnight with 4%  formaldehyde 
in 0.1 M  sodium phosphate buffer, pH 7.4.  The fixed retinal pieces were 
rinsed three times for 10 rain each in 0.1 M phosphate buffer and then de- 
hydrated for 10 min each in 15, 30, and 50% ethanol. Some retinal pieces 
were postfixed for 1 h in 1% wt/vol uranyl acetate in 70% ethanol. The tis- 
sue was dehydrated further for 10 min each in 85 and 90% ethanol, and 
infiltrated for 30 min each in a mixture of LR-gold:ethanol (1:2, vol/vol; 
2:1, vol/vol) at room temperature, followed by infiltration overnight in 100% 
LR-gold at 4°C. The samples then were embedded in fresh resin containing 
initiator and kept at 4°C for 2 h. Polymerization was accomplished by UV 
irradiation,  overnight at  -5°C.  Embedding in  LR White  followed the 
manufacturer's recommendations, and polymerization was at 50°C. 
Thin sections of human retina, collected on Formvar-coated nickel grids, 
were incubated in a blocking solution (PBS, pH 7.4, containing 1% wt/vol 
BSA, 1% vol/vol normal goat serum and 0.02 % wt/vol azide) for 30 minutes 
at room temperature. The grids were blotted briefly with filter paper and 
then floated on 50-/~1 droplets containing either normal human serum or 
CAR antiserum at a  dilution of 1:100, or affinity-purified antibodies ob- 
tained from CAR sera (see below). Incubation was conducted overnight in 
a humidified chamber at room temperature. After rinsing the grids in PBS 
containing 0.1% BSA and 0.1% normal goat serum, sections were incubated 
for  1 h  at room temperature with AuroProbe EM goat anti-human IgG 
(Amersham Corp., Arlington Heights, IL) at a dilution of 1:25 in 0.1% BSA- 
PBS. After thorough washing in 20 mM Tris.HCl, 0.9%  NaCI, pH  8.2 
(Tris.NaCl), sections were fixed for 20 rain in aqueous 2% glutaraldehyde 
and rinsed with water. Some sections were subsequently stained for 3 min 
in 2 % uranyl acetate and 1 rain in lead citrate. Sections were postfixed with 
2% aqueous osmium tetroxide fumes for 1 h and viewed with Zeiss 10 C/A 
transmission electron microscope. 
Preparation of  Human ROS 
Rod outer segments (ROS) were isolated from human retinas according to 
the procedures developed for bovine ROS,  as described by Papermaster 
(1982).  In some experiments, human retinas were disrupted using a Teflon 
pestle and solubilized with 0.15 % wt/vol deoxycholate. After centrifugation 
at 100,000 g (SW'28; Beckman Instruments, Fullerton, CA), the supernatant 
and previously isolated ROS were processed for SDS-PAGE. All isolations 
were done in the presence of 2/~g/ml leupeptin, 4 #g/ml PMSE and 10 
/~g/ml aprotinin. 
SDS-PAGE and Western Blot Analysis 
Treatment of protein samples is described in detail elsewhere (Polans et al., 
1979),  as are the procedures for electrophoresis and transfer of protein to 
nitrocellulose (Polans and Burton, 1988). In some experiments, Immobilon 
(Millipore Corp., Bedford, MA) was used in place of nitrocellulose. Sepa- 
ration of peptide fragments was accomplished with a Tricine-SDS-gel elec- 
trophoresis system (Huang and Matthews, 1990; Schagger and yon Jagow, 
1987) using a 16% polyacrylamide gel. Protein determinations were made 
with a dye binding assay (Bradford, 1976). 
Western blots were rinsed twice in Tris.NaC1, and nonspecific sites were 
saturated by incubation for 45 rain at 37°C with a solution of  Tris.NaC1 con- 
taining 5 % wt/vol BSA. The membrane then was incubated for 1-2 h either 
with CAR antisera at a dilution of 1:500 or affiulty-purified antibody (see 
below). All incubations were performed in 0.1% BSA-Tris.NaCI.  Blots were 
rinsed six times each for 5 rain with 0.1% BSA-Tris .NaCI and then incubated 
for 2 h with a 1:50 dilution of goat anti-human IgO gold conjugate in 0.1% 
BSA-Tris.NaC1 containing 0.4% wt/vol gelatin. After four rinses with 0.1% 
BSA-Tris-NaCI,  blots were rinsed with water (twice for 30 s each) and 
silver-enhanced 10-15 rain according to the manufilcturer's procedures. 
AjOinity Purification of CAR Antibodies 
Procedures for the affinity purification of complex antisera have been pub- 
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protein were incubated with CAR antiserum. A single lane from the blot 
was  stained using gold conjugates  and silver enhancement as described 
above. The stained lane was realigned with the blot, and protein bands cor- 
responding to the sites of antibody staining were excised separately.  Anti- 
body was eluted from excised bands using glycine-HCl,  pH 2.2, followed 
by neutralization with Tris base.  The antibody eluate was quantitated for 
human IgG using an immunogold  procedure (Burton et al.,  1989).  After 
concentrating the eluate in a Centricon 30 tube (Amicon Corp., Danvers, 
MA), the sample was mixed to yield 0.1% BSA, 0.1% normal goat serum 
in either Tris-NaC1 or PBS. 
Purification of the 26-kD CAR Antigen 
ROS from 150 bovine retinas were prepared as described previously  (Wil- 
den and Kiihn,  1982) and finally resuspended in 20 ml of 50 mM Hepes 
buffer, pH 7.5, containing 1.0 mM EDTA and 100 mM NaCI.  The suspen- 
sion was  homogenized  with a  glass-glass  tissue homogenizer and cen- 
trifuged at 48,000 g (J 20.1; Beckman Instruments) for 10 min. The superna- 
tant was collected and the extraction procedure was repeated  three times. 
These steps  were conducted at 40C under dim red illumination.  Calcium 
chloride then was added to the combined supernatants in order to yield a 
final concentration of 2 mM. 
A  Phenyl-Sepharose  column (1.0  ×  4.0 cm) was prepared and equil- 
ibrated with 50 mM Hepes  buffer,  pH 7.5, containing 2 mM CaC12 and 
100 mM NaCI.  The bovine ROS extract was applied  to the column, and 
the column was washed with equilibrating  buffer at a rate of 15 ml/h until 
the A2s0 nm returned to baseline. Bound material was eluted with 50 mM 
Hepes buffer, pH 7.5, containing 10 mM EDTA and 100 mM NaC1 at a rate 
of 5 ml/h.  l-ml fractions were  collected, and aliquots were  subjected  to 
SDS-PAGE and Western blot analysis using CAR antiserum. 
Fractions containing the 26-kD CAR antigen were combined and dia- 
lyzed  against  1 liter of  10  mM  bis[2-hydroxymethyl]iminotris[hydroxy- 
methyl]-methane (BTP) buffer, pH 8.4. Aliquots  containing 0.5-1.0 mg of 
protein were applied to a Mono Q column (HR 5  x  50 mm; Pharmacia 
Fine Chemicals, Piseataway, NJ) equilibrated with 10 mM BTP buffer, pH 8.4. 
The column was developed with a linear gradient of NaCI (0-0.25 M) dur- 
ing 20 min at a rate of 0.5 ml/min. 0.5-ml fractions were collected,  and ali- 
quots were analyzed  by SDS-PAGE and Western blot analysis using CAR 
antiserum. The 26-kD CAR antigen eluted at ~100 mM NaCI. 
Amino Acid Sequence Analysis 
The purified 26-kD protein was lyophilized and S-carboxymethylation  was 
performed following the methods described by Crestfield  et al. (1963). Cy- 
anogen bromide (CNBr) cleavage of the S-carboxymethylated  protein was 
performed over a 72-h period according to the methods published by Lai 
(1968). CNBr peptide fragments were separated  by Tricine-SDS-gel  elec- 
trophoresis (Huang and Matthews,  1990;  Schagger and von Jagow, 1987) 
and electroblotted to Immobilon (Millipore Corp.) for sequence and amino 
acid analysis (Matsudaira,  1987). Additionally, the purified 26-kD protein 
was  subjected to  cleavage  at lysyl  residues  with endoproteinase Lys-C 
(Boehringer-Mannheim  Biochemicals, Indianapolis, IN), and peptides were 
isolatr..d by narrowbone RP-HPLC ('v~dac, Hesperia, CA) using the Applied 
Biosystems model 130 system (Applied Biosystems,  Inc., Foster City, CA) 
(Crabb et al.,  1986). 
Phenylthiocarbamyl  amino acid analysis  was  performed according to 
West and Crabb (1990)  using an Applied Biosystems  automatic system 
(models  420/130/920).  HC1  vapor phase  hydrolysis  was  performed  at 
150°C for 1 h. Automatic Edman degradations  were performed as previ- 
ously described (Crabb et al., 1988) with an Applied Biosystems gas phase 
sequencer (model 470) and an on-line phenylthiohydantoin  amino acid ana- 
lyzer (model 120) using the 03RPTH sequencer program and the manufac- 
turer's recommended program and solvents  for the PTH analyzer. 
Materials 
Human donor eyes were obtained from the Lions Eyebank of Oregon, 
Samaritan Hospital and Medical Center (Portland, OR). CAR antisera were 
the generous gift of Drs. C. Thirkill and J. Keltner (University of California 
at Davis).  Sera also were obtained from Drs. R. Chenoweth and T. Shults 
(Good Samaritan Hospital and Medical Center) and Drs. R. Weleber and 
Figure 1. Fluorescent detection of CAR antiserum staining of human retina. Cryosections of rinsed and formaldehyde-fixed human retinas 
were incubated with a  1:100 dilution of CAR antiserum (,4) or normal human serum (B) and subsequently incubated with a biotinyl-goat 
anti-human IgG and a  streptavidin-Texas red conjugate.  Abbreviations: GCL,  ganglion cell layer; INL, inner nuclear layer; IPL, inner 
plexiform layer; ISL,  inner segment layer; ONL, outer nuclear layer;  OPL, outer plexiform layer; OSL, outer segment layer. 
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rum to a nitrocellulose blot of human 
ROS proteins. After separation by SDS- 
PAGE, human ROS proteins were stained 
with Coomassie brilliant blue (A). Ni- 
troceUulose blots of human ROS pro- 
teins were incubated sequentially with 
CAR antiserum  (1:500 dilution),  goat 
anti-human IgG gold complex and silver 
enhanced  (B). A prominent  band at 26 kD 
is labeled by the antiserum. Minor bands 
also could be detected in the 68-95 kD 
range. Molecular weight standards were: 
B-galactosidase  (116  kD), phosphorylase 
b  (94 kD),  BSA (67 kD),  ovalbumin 
(43 kD),  carbonic anhydrase (30 kD), 
and soybean trypsin inhibitor (20.1 kD). 
J. Rosenbaum (Oregon Health Sciences University).  Biotinyl-goat anti-hu- 
man IgG, Auroprobe goat anti-human  IgG (EM and BL grade), normal goat 
serum and the silver enhancement kit were the products  of Janssen Phar- 
maceutica (distributed by Amersham Corp.).  Streptavidin-Texas Red was 
purchased from Amersham Corp.  (Arlington Heights,  IL). Paraformaide- 
hyde, glutaraldehyde  and osmium tetroxide, EM grade, were obtained from 
Electron Microscopy  Sciences  (Ft. Washington,  PA). LR-White and LR- 
Gold were purchased from Polysciences,  Inc., (Warrington,  PA). Electro- 
phoresis reagents were products of Bio-Rad Laboratories (Richmond, CA). 
Immobilon and nitrocellulose  were obtained from Millipore Corp. Phenyl- 
Sepharose was purchased from Pharmacia Fine Chemicals.  All other chem- 
icals were obtained from Sigma Chemical  Co.  (St.  Louis,  MO). 
Results 
Fig.  1 illustrates the binding of CAR antiserum to a cryo- 
section of human retina, as detected by fluorescence light 
microscopy using a biotinyl-secondary antibody and strep- 
tavidin-Texas red conjugates. Fig. 1 A shows intense labeling 
by the CAR antiserum of the outer nuclear layer, as well as 
the inner and outer segment layers of the retina. A subpopu- 
lation of cell bodies in the inner nuclear layer also binds the 
antiserum. These results were obtained with CAR antisera 
from patients diagnosed either with oat-cell carcinoma of  the 
lung or ovarian adenocarcinoma. In contrast, when normal 
human serum is substituted for the CAR antiserum, sections 
are not labeled (Fig. 1 B). These experiments confirm previ- 
ous observations that CAR antisera contain autoantibodies 
that can bind to retinal sites (Grunwald et al.,  1985; Kelt- 
ner  et  al.,  1983;  Kornguth et  al.,  1982;  Thirkill  et  al., 
1987,  1989). 
To identify the retinal antigen(s) that bind CAR autoanti- 
bodies, human ROS or retina were subjected to SDS-PAGE, 
and the proteins were transferred to nitrocellulose paper for 
staining with CAR antiserum. The protein staining pattern 
of human ROS obtained by SDS-PAGE is shown in Fig.  2 
A, and Fig. 2 B shows the corresponding nitrocellulose blot 
reacted sequentially with CAR antiserum and goat anti-hu- 
man IgG gold complex, A prominent band at 26 kD is la- 
beled by the CAR antiserum, while several less intense bands 
in the 68-95-kD range also can be detected. We find that the 
26-kD band is uniquely associated with the five CAR an- 
tisera tested. Human antisera which bind to different sites in 
the retina (Fig. 3 A), label, for instance, additional bands in 
the 68-95-kD range (Fig. 3 B). Labeling of the 26-kD band 
by antisera obtained from non-CAR patients was  not ob- 
served in these experiments. Sera were tested from two pa- 
tients diagnosed with retinitis pigmentosa, three individuals 
who were free of  cancer but whose sera demonstrated retinal 
labeling, three cancer patients without any associated retinal 
labeling, and three individuals without cancer or detectable 
retinal labeling. 
Since more than one retinal antigen appears to be recog- 
nized by the CAR antiserum, the identity of the antibody- 
antigen interaction that underlies the observed labeling of  the 
retina is uncertain. To address this issue, complex CAR an- 
tisera were fractionated to provide afffinity-purified antibod- 
ies (see Materials and Methods). Fig. 4 A shows the results 
of applying affinity-purified antibody against the 26-kD pro- 
tein to cryosections of human retina. As shown previously 
with whole antiserum, antibodies to the 26-kD protein in- 
tensely labeled the outer nuclear layer and inner and outer 
segment layers of the retina. Antibodies ehted from proteins 
in the 68-95-kD range only slightly labeled the plexiform 
layers of the retina (Fig. 4 B). We can conclude from these 
experiments that the principal,  if not sole, retinal antigen 
recognized by CAR autoantibodies appear to be the 26-kD 
protein. Interestingly, application of  CAR antisera to sections 
of human retina which had been embedded in plastic resin, 
either LR-gold or LR-white, showed a  diminution of label 
(Fig. 4 C). Whereas binding of anti-26-kD antibodies to the 
outer nuclear layer was still visible, binding to the outer seg- 
ments fell below detection by fluorescence light microscopy. 
The difference in labeling intensity between frozen tissue and 
tissue embedded in plastic may reconcile our results with a 
previous report that demonstrated CAR labeling of the outer 
nuclear layer but not the inner and outer segments of retinal 
tissue which had been embedded in LR-white (Thirkill et al., 
1989). 
The binding of CAR antisera to plastic-embedded tissue 
could be detected by an EM-immunocytochemical approach. 
In preliminary experiments, we observed that the binding of 
CAR antisera was suppressed in tissue that had been treated 
with glutaraldehyde. Although the ultrastructural preserva- 
tion of donor tissue normally obtained with glutaraldehyde 
was difficult to maintain with formaldehyde, antibodies to 
the 26-kD protein were found to label nuclei and the sur- 
rounding cytoplasm of photoreceptor cell bodies in the outer 
nuclear layer (Fig. 5 A).  Successive sections, incubated ei- 
ther with normal human IgG or antibodies to the 68-95-kD 
proteins, were not labeled upon further incubation with the 
immunogold complex (Fig. 5 B). In contrast to controls, the 
inner segments (Fig. 5 C) and outer segments (Fig. 5 D) of 
both rods and cones also were observed to bind affinity-puri- 
fied antibodies to the 26-kD protein. The EM-immunocyto- 
chemical results, therefore, support our fluorescence studies 
which demonstrated the presence of the 26-kD antigen in the 
inner and outer segment layers of the retina, as well as the 
outer nuclear layer. These immunocytochemical studies are 
further corroborated by our Western blot analyses, in which 
preparations of outer segments (Fig. 2 B) and of the remnant 
retina both contained the 26-kD protein (data not shown). 
To characterize the 26-kD CAR antigen further, the pro- 
tein was purified by a two-step chromatographic procedure. 
Bovine ROS  were homogenized in the presence of 1 mM 
EDTA and no added calcium. Under these conditions the 26- 
kD protein was extracted into a soluble fraction, whereas, 
in the presence of excess calcium,  the protein mostly re- 
mained bound to ROS membranes. An aliquot of the soluble 
extract was subjected to SDS-PAGE, and the protein staining 
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a patient  without cancer but whose serum did bind to retina  (A). Note the intense staining  of the inner segment layer and both plexiform 
layers,  whereas the outer segments  and outer nuclear layer were unlabeled.  Nitrocellulose blots of human ROS protein stained  with the 
same antiserum (B) did not label the 26-kD band (C). Additional bands in the 68-95-kD range were labeled by this antiserum.  All incuba- 
tions were conducted as described in the legend  of Fig.  1 and Materials  and Methods. 
pattern  is given in Fig. 6  A.  Excess calcium was added to 
the remaining soluble extract, and this material was applied 
to a Phenyl-Sepharose column. The majority of extractable 
protein  ran  unretarded  through  the  colunm  (Fig.  6  B), 
whereas bound material,  consisting primarily of the 26-kD 
protein, could be eluted from the Phenyl-Sepharose column 
by the addition of EDTA (Fig. 6 C). This calcium-dependent 
binding to Phenyl-Sepharose strongly suggested that the 26- 
kD protein might be a calcium-binding protein.  Final puri- 
fication of the protein was accomplished by a  second chro- 
Figure 4.  Affinity-purified  CAR antibody staining  of cryosections and plastic  sections  of human retina.  Affinity-purified  antibodies  to the 
26-kD protein (see Materials and Methods) were used to stain cryosections of retina (A) according to the procedures given in the legend 
of Fig. 1 and Materials and Methods. Like the CAR antiserum, antibodies  to the 26-kD protein intensely  labeled the ONL, ISL and OSL. 
Antibodies to the 68-95-kD proteins of human ROS which are depicted in Fig. 2 only slightly stained the plexiform layers of cryosectioned 
retina (B). CAR antiserum showed reduced labeling of the outer nuclear layer and no labeling of the inner and outer segment layers when 
the retina was embedded in a plastic  resin,  LR-white  (C). 
Polans et al. Identification of the CAR Antigen  985 Figure 5. R~tinal  binding of afffinity-purified  antibodies to the 26-kD protein, as detected by EM. Human retinas were fixed in formaldehyde 
and stained with affinity-purified  antibodies to the 26-kD protein. Antibody binding was detected with a goat anti-human IgG gold complex 
(10 nm). Human donor retina showed intense labeling of the nuclei and surrounding cytoplasm of photoreceptor cell bodies in the outer 
nuclear layer (.4). The asterisk indicates the absence of background label in a region between three cell bodies. Sections incubated with 
normal human IgG were not labeled upon subsequent incubation with the anti-human IgG gold complex (B). The inner segments of three 
photoreceptors are labeled with antibodies to the 26-kD protein (C), while the surrounding plastic support is devoid of label (asterisk). 
The darker profiles (M) are mitocbondria which appear almost negatively stained when embedding a nonosmicated tissue in a hydrophilic 
plastic !~ LR-gold. Pbotoreceptor outer segments (OS) also are labeled (D). 
matographic step using a Mono Q column. The column was 
developed with a linear gradient of NaC1,  and the purified 
protein, which we designate as p2~, was eluted at ",,100 mM 
NaCI.  Fig.  6 D  shows  a  sample from the purified protein 
fraction; no other protein bands could be detected. Molecu- 
lar  weight  standards  were run  in  lane E.  Approximately 
275 t~g of  purified protein was obtained from 150 retinas. An 
aliquot of the purified protein was subjected to SDS-PAGE 
and immunoblotting with a CAR antiserum, and the:positive 
staining of the 26-kD band is shown in Fig. 6 E 
Our initial attempt to sequence purified p2~ revealed that 
the NH2 terminus was blocked. Therefore, the protein was 
cleaved with CNBr. The CNBr fragments were resolved by 
modified SDS-PAGE and electroblotted to Immobilon for di- 
rect sequencing. Edman analysis of the immobilized CNBr 
peptides yielded the partial sequence GFFGKKDDDKLT- 
EKEFIEGXLAN.  The purified protein (~7  t~g) also was 
subjected to enzymatic digestion at lysyl residues with endo- 
proteinase Lys-C, and fragments were purified by narrow- 
bore RP-HPLC before sequencing. Table I shows the partial 
The Journal of Cell Biology, Volume  112, 1991  986 Figure 6. Purification of the CAR antigen. Bovine rod outer seg- 
ments were extracted with EDTA, and the soluble fraction (after 
adjusting the calcium concentration) was applied to  a  Phenyl- 
Sepharose column. An aliquot of the soluble extract was separated 
by SDS-PAGE, and the protein staining pattern is shown in lane A. 
Protein which did not bind to the column is shown in lane B, 
whereas bound material which could be  eluted with EDTA is 
stained in lane (7. The 26-kD protein represented the majority of 
protein which was bound to the column.  The eluted material 
depicted in lane C was further purified by Mono Q chromatography, 
and an aliquot of the final sample is shown in lane D. Molecular 
weight standards in lane E were: phosphorylase b (94 kD); bovine 
serum albumin (67 kD); ovalbumin (43 kD); carbonic anhydrase 
(30 kD); soybean trypsin inhibitor (20.1 kD); and c~-lactalbumin 
(14.4 kD). An immunoblot of the purified fraction shown in lane 
D was prepared according to the procedures given in the legend of 
Fig. 2 and in Materials and Methods. CAR staining of the immuno- 
blot is shown in lane F. 
amino acid sequence of p:6 and the homology it shares with 
a cone photoreceptor-specific protein, visinin (Yamagata et 
al.,  1990).  The two proteins share •60%  identical amino 
acids in the  157  residues that have been sequenced in p26 
and almost 90%  homology if considering conservative re- 
placements (Dayhoff  et al., 1969).  Three regions within the 
visinin sequence are clearly homologous with calmodulin 
and troponin C (Yamagata  et al.,  1990)  and represent cal- 
cium binding domains of the E-F hand structure.  Corre- 
sponding regions within the p~ sequence revealed ,,090% 
homology to visinin. Recently, a more complete amino acid 
sequence of p26 has been determined by others characteriz- 
ing a protein they term recoverin (Hurley, J., K. Walsh, and 
A. Dizhoor, personal communication). In concurrence with 
our results, these investigators also have recognized the ho- 
mology with visinin, as well as with other calcium binding 
proteins of the calmodulin family. 
Discussion 
We have confirmed previous reports that the sera from CAR 
patients contain autoantibodies that bind to the retina (Kelt- 
ner et al., 1983; Kornguth et al., 1982; ThirkiU et al., 1987, 
1989). We have afffinity-purified the autoantibodies  from  com- 
plex CAR sera to identify the principal, if not sole, retinal 
antigen as a 26-kD protein. In EM immunocytochemical  ex- 
periments, we localized the 26-kD protein to the cell bodies, 
inner and outer segments of  both rods and cones. We purified 
the rod protein by a simple chromatographic procedure and 
demonstrated, using partial amino acid sequence analysis, 
that the protein shares  extensive homology with a  cone- 
specific protein, visinin. Both visinin and the rod protein, 
p26, contain within their sequences the proper motifs for the 
binding  of calcium.  Concurrent  investigations in  several 
laboratories  are  examining the role  which these calcium 
binding proteins might play in phototransduction, perhaps 
by regulating guanylate  cyclase activity (Hurley, 1990; Koch, 
1990;  Yamagata  et al.,  1990). 
Two laboratories recently have presented preliminary data 
on the isolation of a protein similar to visinin but isolated 
from rods (Hurley,  1990;  Koch,  1990).  A  comparison of 
amino acid sequences demonstrates that 1  ~6 is the same pro- 
tein (Hurley, J., K. Walsh, and A. Dizhoor, personal com- 
munication). Thus, CAR autoantibodies recognize a retinal 
protein that is involved, at least, in the calcium-dependent 
regulation of guanylate cyclase. Since CAR antisera label 
both rods and cones, it appears likely that 1  ~6 and visinin 
are the respective antigens, although p26 may be present in 
both types of photoreceptors and is the sole antigen.  Al- 
though two other calcium-binding proteins, calretinin and 
calbindin, are present in cones but not rods and may bind 
CAR autoantibodies, they share little homology with visinin 
or p:6 (Rogers, 1987; Yamagata et al.,  1990).  Nonetheless, 
the definitive identification of the cone antigen awaits  the 
purification of these calcium binding proteins in order to de- 
termine which ones, in addition to 1  ~6, bind CAR autoanti- 
bodies.  While  discussing other  retinal  antigens,  we  also 
should consider that CAR, like retinitis pigmentosa, may 
consist of a group of retinal degenerations. As studies con- 
tinue, other retinal antigens may be associated with the au- 
toimmune component of the disease. The identification and 
localization of these antigens may help establish a correla- 
tion between the affected retinal antigen and, for instance, 
the severity and progression of the disease. 
Owing to the characterization of p26, it now should be 
possible to examine biopsy tissue obtained from CAR pa- 
tients and look for the expression of an immunoreactive 
calcium-binding protein or shared determinant. The exami- 
nation of tissue from a patient with a similar tumor but no 
associated retinopathy would determine the extent to which 
the expression of the protein correlates with the retinopathy, 
and whether additional mechanisms dictate which cancer pa- 
tients will develop the retinal disorder. Finally, it is interest- 
ing to note that autoantibodies generated in Eaton-Lambert 
myasthenic syndrome bind  to  calcium  channels  (DeAiz- 
purua et al.,  1988; Kim and Neher,  1988;  Newsom-Davis, 
1985); thus, recognition sites for calcium may be a common 
element among different paraneoplastic syndromes. 
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Visinin  1 
:6 
41 
81 
121 
161 
MGNSRSSALSREVLQELRASTRYTEEELSRWYEGFQRQCS 
SGALSKEILEELQLNTKFTEEELSSWYQSFLKESP 
1  I  I  I 
Endol  Endo2  Endo3 
DGRIRCDEFERIYGNFFPNSEPQGYARHVFRSFDTNDDGT 
SGRITRQEFQTIYS  FFPEADPK  YAQHVFRSFDAN 
I  I  I 
Endo 4  Endo 5  Endo 6 
LDFREYI  I  ALHLT  S  SGKTHLKLEWAF  S  LFDVDRNGEVSKS 
EYVIALHMTSAGKTNQKLEWAFSLYDVDGNG 
I  I 
Endo 7  Endo  8 
EVLEI  ITAIFKMIPEEERLQLPEDENSPQKRADKLWAYFN 
MISPEDTKHLPEDENTPEK  IWGFFG 
I  I  I  I 
Endo9  Endol0  [ 
KGENDKIAEGEF  IDGVMKNDAIMRL  IQYEPKK 
KKDDDKLTEKEF  I  EGTLANKE  I  LRL  I  QFEPQK 
I  I 
Endo  11  Endo  12 
I 
CNBr 
40 
80 
120 
160 
The amino acid sequence of p~6 and visinin (Yamagata et al.,  1990) are given in single letter code (Eur. J. Biochem.  1968,  5:151-153).  The double and single 
dots indicate  identical  amino acids and conserved replacements, respectively (Dayhoff et al., 1969).  The paptide fragments from p26 are underlined according to 
their isolation  either by Endoproteinase Lys-C cleavage (Endo)  or CNBr cleavage. 
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